Register Today for the Premier Translational Research in Oncology Meeting
7th International Symposium on Translational Research in Oncology
October 16 - 19, 2008
Hyatt Regency Huntington Beach
Huntington Beach, CA
At this premier scientific meeting, the world's leading researchers gather to present data and discuss recent directions in oncology research, with a focus on translating the most recent laboratory developments into the development of treatments that improve clinical outcomes for cancer patients. The program, developed under the direction of co-chairs Dennis J. Slamon, MD, PhD, and John Crown, MD, MPH, includes relevant didactic presentations and compelling, interactive discussions.
Faculty are carefully selected from among the researchers at the forefront of the translational work in the topic, whether from academia, government, or industry. The program encourages networking and interaction between the attendees and the renowned faculty members.
Agenda
Thursday, October 16
12:00 PM - 6:00 PM Registration
6:30 PM - 9:30 PM Welcome Reception
Friday, October 17
7:00 AM - 8:00 AM Breakfast
8:00 AM - 10:00 AM Session I: Growth Factors and Growth Factor Receptors
Chair: Dennis J. Slamon, MD, PhD
UCLA David Geffen School of Medicine
The IGFR Signaling Pathway as a Novel Therapeutic Target
Renato Baserga, MD
Sidney Kimmel Cancer Center
IGF1 Pathway
Frank Calzone, PhD
Amgen
EGF Pathway
Bruce Johnson, MD
Dana Farber Cancer Institute
HER2 (PanHER) Pathway
Ian Taylor, PhD
Pfizer
MET inhibition
Jamie Christensen, PhD
Pfizer
HDAC Inhibition
Ramona F. Swaby, MD
Fox Chase Cancer Center
10:00 AM - 10:30 AM Break
10:30 AM - 12:30 PM Session II: Steroid Hormonal Receptors and Their Manipulation
Chair: Mitch Dowsett, MD, PhD
Royal Marsden Hospital
Abiraterone: A Novel Hormone Inhibitor
Timothy Yap, MB BS, MRCP, BSc
Royal Marsden Hospital
Pharmacogenetics of Endocrine Therapy
James M. Rae, PhD
University of Michigan
Non-ERE-Mediated Effects of ER: Significance for Response and Resistance to Antiendocrine Therapies
Dorraya El-Ashry, PhD
University of Miami
Molecular Changes With Endocrine Therapy: Implications for Integration With Targeted Therapy
Mitch Dowsett, MD PhD
Royal Marsden Hospital
12:30 PM - 2:00 PM Lunch
2:00 PM - 4:00 PM Session III: Apoptosis and Programmed Cell Death
Chair: Tak Mak, MD
Princess Margaret Hospital
PI3-Kinase Signaling and Therapeutic Resistance
Eric Holland, MD
Memorial Sloan-Kettering Cancer Center
Bcl-2 Inhibition
Gordon Shore, PhD
McGill Unversity
TRAIL Receptor
Wafik El-Deiry, MD, PhD
University of Pennsylvania
What Will be the Next Generation of Cancer Targets?
Tak Mak, MD
Princess Margaret Hospital
4:00 PM Afternoon Refreshments
Saturday, October 18
7:00 AM - 8:00 AM Breakfast
8:00 AM - 10:00 AM Session IV: Malignant Angiogenesis and Antiangiogenic Therapies
Chair: George Sledge, MD
Indiana University
Angiopoietin-Tie2 Signaling Pathway
Charles Lin, PhD
Vanderbilt University
Resistance to VEGF-Targeting Agents
Robert Kerbel, PhD
University of Toronto
Lessons Learned From Clinical Trials of Antiangiogenic Agents
George Sledge, MD
Indiana University
10:00 AM - 10:30 AM Break
10:30 AM - 12:30 PM Session V: Malignant Stem Cells as Targets in Oncology
Chair: Hasan Korkaya, DVM, PhD
University of Michigan
Hedgehog Signaling Pathway and Regulation of Bmi-1
Frederic J. de Sauvage, PhD
Genentech
IL-4 Signaling in Colon Cancer Stem Cells
Giorgio Stassi, PhD
University of Palermo
Wnt/Beta-Catenin Signaling Pathway
Paul Polakis, PhD
Genentech
PI3-K/Akt Pathway Role on Mammary Stem Cells
Hasan Korkaya, DVM, PhD
University of Michigan
12:30 - 1:30 PM Lunch
1:30 - 2:00 PM Special Presentation
Fran Visco, JD
National Breast Cancer Coalition Foundation
2:00 - 4:00 PM Session VI: Immunotherapies and Vaccine Strategies
Chair: John Glaspy, MD
UCLA Jonsson Comprehensive Cancer Center
T-Cells as Therapy for Metastatic Cancer: Clinical Results
James Yang, MD
National Institutes of Health
Antibodies for Modulating Anti-Tumor Responses
Antoni Ribas, MD
UCLA Jonsson Comprehensive Cancer Center
Anti-CTLA4 Strategies With and Without Vaccines
John Glaspy, MD
UCLA Jonsson Comprehensive Cancer Center
Clinical Development of PD-1 Blockade in Cancer Therapy
Suzanne L. Topalian, MD
Sidney Kimmel Comprehensive Cancer Center
Therapeutic Conversion of Procarcinogenic Immune Pathways to Anti-Tumor Immune Responses
Drew Pardoll, MD, PhD
Johns Hopkins University School of Medicine
Sunday, October 19
7:00 - 8:00 AM Breakfast
8:00 AM - 10:00 AM Session VII: Signal Transduction: Targets in the Malignant Signaling Process
Chair: Neal Rosen, MD. PhD
Memorial Sloan-Kettering Cancer Center
MEK Inhibition
David Solit, MD
Memorial Sloan-Kettering Cancer Center
mTOR Inhibition
Jay Gibbons, PhD
Wyeth
Ras Signaling
David Tuveson, PhD
Cancer Research UK Cambridge Research Institute
Akt Inhibition
Neal Rosen, MD, PhD
Memorial Sloan-Kettering Cancer Center
10:00 AM - 10:15 AM Break
10:15 AM - 12:15 PM Session VIII: Identification of Signaling Pathways and Genetic Markers in Cancer
Chair: Lajos Pusztai, MD, PhD
MD Anderson Cancer Center
Genomic Disregulation of Cancer Cells: Opportunities for New Drug Development
Neil Spector, MD
Duke University
The PI3-K and mTOR Pathways as Novel Therapeutic Targets for Breast Cancer
Funda Meric-Bernstam, MD
MD Anderson Cancer Center
Cell Line Models of Targeted Therapies
Paul Spellman, MD
University of California, Berkeley
Cell Line Models of Drug Synergy
Richard S. Finn, MD
UCLA David Geffen School of Medicine
Discovery of the Next Generation of Drugs Through the Analysis of Human Genomic Data
Lajos Pusztai, MD, PhD
MD Anderson Cancer Center
12:15 PM - 12:30 PM Concluding Remarks
12:30 PM Box Lunch and Departures
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
In order to receive credit, participants must attend the session and submit a credit application and evaluation form to symposium staff at the end of the program. Certificates will be mailed within 6-8 weeks following the program.
